Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Unknown 2Completed 1

Sponsor Class

OTHER 68INDUSTRY 12UNKNOWN 3OTHER_GOV 2NIH 2NETWORK 2INDIV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2NET 1Endocrine 1

Conditions

Extrapancreatic Neuroendocrine Tumor 1Advanced Pancreatic Cancer 1Adenoma, Islet Cell 1

Interventions

Paclitaxel 20Capecitabine 18S 1 (combination) 17Cisplatin 15Oxaliplatin 11Radiotherapy, Intensity-Modulated 9apatinib 8Epirubicin 8Docetaxel 8Carboplatin 8Radiotherapy 7Irinotecan 7titanium silicide 6sintilimab 6pyrotinib 6nimotuzumab 6anlotinib 6Drug Therapy 6Albumin-Bound Paclitaxel 6130-nm albumin-bound paclitaxel 6nedaplatin 5camrelizumab 5Temozolomide 5Etoposide 5Bevacizumab 5nabiximols 4Vinorelbine 4Trastuzumab 4Radiation Dose Hypofractionation 4Pemetrexed 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
UNKNOWN × Interventional × Tegafur × Clear all
NCT03415802 2021-02-01

Efficacy and Safety of Nab-Paclitaxel Plus S-1 in the First-line Treatment of Advanced Pancreatic Cancer

ChineseAMS

Phase 2 Completed
32 enrolled
Gastrointestinal

Advanced Pancreatic Cancer

NCT03204019 2017-06-29

A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor

ChineseAMS

Phase 2 Unknown
60 enrolled

Adenoma, Islet Cell

NCT03204032 2017-06-29

A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor

ChineseAMS

Phase 2 Unknown
60 enrolled
EndocrineGastrointestinalNET

Extrapancreatic Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡